Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions: Antibiotic Prophylaxis; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Rheumatoid Arthritis
Interventions: Lovastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Depression, Bipolar
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 38
States / cities: Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 33 more

Conditions: Obesity, Overweight
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 39 more

Conditions: Health Adult Subjects
Interventions: Omaveloxolone, Moxifloxacin; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: PHX1149T, Placebo; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 13
States / cities: Norwalk, California • Orange, California • Santa Ana, California + 10 more

Conditions: Obstructive Sleep Apnea
Interventions: RXiBreeze PAP System, Model RXiBreeze 20A; Device
Lead sponsor: Resvent Holding USA LTD; Industry
Eligibility: 22 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 9
States / cities: Burlingame, California • Chula Vista, California • Mountain View, California + 6 more

Conditions: Septic Shock, Shock, Septic, Lactic Acidosis, Thiamine Deficiency
Interventions: Thiamine, Placebos; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Posttraumatic Stress Disorder
Interventions: High THC cannabis, High CBD cannabis, THC/CBD cannabis, Placebo cannabis; Drug
Lead sponsor: Multidisciplinary Association for Psychedelic Studies; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 50
States / cities: Mountain Brook, Alabama • Avondale, Arizona • Flagstaff, Arizona + 46 more

Conditions: Thyroid Eye Disease (TED)
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Tuscon, Arizona • Inglewood, California • Newport Beach, California + 25 more

Conditions: Obesity
Interventions: APD356; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Cryptosporidium Infection, Cryptosporidiosis
Interventions: Cryptosporidium parvum oocysts (ABO809); Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: VBY-036; Drug
Lead sponsor: Virobay Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Pain, Postoperative
Interventions: VVZ-149 Injections, Placebo; Drug
Lead sponsor: Vivozon, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Anaheim, California • Salt Lake City, Utah

Conditions: Plaque Psoriasis
Interventions: calcitriol ointment, placebo comparator; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Beverly Hills, California • Sacramento, California • Louisville, Kentucky + 9 more

Conditions: Demodex Blepharitis
Interventions: GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID, GLK-321 high dose QD, Placebo BID; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more

Conditions: Non-infectious Anterior Uveitis, Uveitic Glaucoma
Interventions: TRS01, FDA approved steroid eye drop (masked); Drug
Lead sponsor: Tarsier Pharma; Industry
Eligibility: 0 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Alzheimer's Disease
Interventions: Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 41
States / cities: Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more

Conditions: Pulmonary Artery Hypertension
Interventions: GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more

Conditions: Hepatitis B
Interventions: Alendronate, Hepatitis B Vaccine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Glimepiride, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 46
States / cities: Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more

Conditions: Atopic Dermatitis
Interventions: F# 11054-010, F# 10495-053; Device
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Albuquerque, New Mexico

Search by objective public record fields.

Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

A TQTc Study for Omaveloxolone

Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

Study of the Resvent RXiBreeze™ PAP System to Treat Obstructive Sleep Apnea

Thiamine Supplementation in Patients With Septic Shock

Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Safety and Efficacy of APD356 in the Treatment of Obesity

Study of Efficacy and Safety of ABO809 in Healthy Participants

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing

Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Bunionectomy

Plaque Psoriasis Study in Pediatric Subjects

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children